ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
ChromaDex Corp. (NASDAQ:CDXC) announced new findings supporting the efficacy of its proprietary Niagen® (nicotinamide riboside or NR) in enhancing neurodegenerative biomarkers associated with aging. A recent peer-reviewed study found that NR supplementation significantly increased NAD+ levels in neuron-derived extracellular vesicles and reduced biomarkers linked to Alzheimer’s disease, like Aβ42. This research builds on previous studies supporting NR’s benefits for cognitive health and sets the stage for future trials, including one focused on older adults with mild cognitive impairment.
- NR supplementation significantly increased NAD+ levels in neuron-derived extracellular vesicles.
- The study reduced Aβ42 levels, a marker for Alzheimer’s disease.
- Future trials are planned for NR's effects on older adults with mild cognitive impairment.
- None.
Results from this study on healthy subjects support previous research demonstrating that NR supplementation may impact neurodegenerative biomarkers commonly associated with aging
“We believe biomarkers of brain health are continuing to develop and will be of great importance as humans live longer, especially as age is the number one risk factor for most conditions seen in older adults,” said
The brain is particularly vulnerable to alterations in NAD+ levels during aging due to the high energetic demand of neurons. Restoring brain NAD+ concentration using NR has shown strong efficacy in improving key features of neurodegenerative disorders in animal models, and augmenting brain-based NAD+ metabolism has emerged as a potential strategy for neurological disorders.
“These preliminary results in a small group of subjects provide some insight into how NR may impact NAD+ metabolism in the brain and affect important biomarkers of neurodegenerative disease. We are currently following up on these preliminary findings with a follow-up clinical trial of oral NR supplementation in older adults with mild cognitive impairment, a prodromal form of Alzheimer’s disease (NCT03482167),” said Dr.
The new study analyzed plasma samples from 22 healthy middle aged and older adults who completed a randomized, double-blind, placebo-controlled clinical study of oral supplementation with 1000 mg of NR per day for six weeks. The original study, which was published in 2018 in the journal
- NR supplementation significantly increased NAD+ in NEVs, suggesting an increase in neuronal NAD+ levels.
- In those with an increase in NAD+, NR supplementation also decreased NEV levels of Aβ42, and biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.
- The changes in Aβ42 did not correlate with changes in NAD+, suggesting that NR may be inducing unique effects that are independent of NAD+ changes.
These findings support the ability of oral NR supplementation to augment NAD+ levels in the brain and other neuronal tissue and modify biomarkers related to neurodegenerative pathology in humans. Further, the results suggest NEVs may serve as a blood-based method for monitoring the physiologic response to NR in the brain.
Such results are promising and will set the foundation for further research evaluating NR supplementation in neurodegenerative disorders.
For additional information on the science supporting Niagen® visit www.chromadex.com.
About
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether results of the study are promising, whether it demonstrates NR supplementation may impact neurodegenerative biomarkers, or whether this study builds upon a previous clinical study that demonstrated the promising effects of NR supplementation on Parkinson’s disease patients and will pave the way for future brain-related research. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005048/en/
ChromaDex Media Contact:
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
1-917-929-7600
tshumaker@lifesciadvisors.com
Source: